Low-dose aspirin has no impact on systemic level of serine protease inhibitors in healthy volunteers

Transl Res. 2009 Jun;153(6):272-4. doi: 10.1016/j.trsl.2009.03.001. Epub 2009 Mar 28.

Abstract

Low-dose aspirin (100 mg/day) was recently found to increase serum levels of alpha-1 protease inhibitor (A1-PI). Here, we studied the serum levels of 2 major serine protease inhibitors, A1-PI and serine leukocyte protease inhibitor (SLPI), in 10 Helicobacter pylorinegative healthy volunteers (HVs) treated with low-dose aspirin alone and in combination with other drugs.(1) Neither the treatment with low-dose aspirin alone or in combination altered serum levels of both serine protease inhibitors. The previously described increase of A1-PI levels by low-dose aspirin was most likely caused by multiple endoscopies within a few days, which caused a systemic stress response.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Aspirin / administration & dosage*
  • Female
  • Humans
  • Male
  • Secretory Leukocyte Peptidase Inhibitor / blood
  • Serine Proteinase Inhibitors / blood*
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor
  • Serine Proteinase Inhibitors
  • Aspirin